In order to continue this growth course, Idoven is looking for further partnerships, working intensively on the performance of its own AI tools and also evaluating the usefulness of its solutions in clinical use. One figure documents the importance of global visibility for start-ups and thus, for example, participation in internationally successful trade fair events such as MEDICA: Idoven has already succeeded in acquiring financing in the amount of almost $ 20 million for the realization of upcoming projects and further development.

Healthcare Innovation World Cup: the next generation of intelligent medtech devices


Start-ups, scale-ups and smaller mid-sized companies might also be interested in participating (and applying for free) in the 15th `Healthcare Innovation World Cup'. The focus here is on intelligent “Internet of Medical Things” (IoMT) solutions, e.g., digital biomarkers, smart band-aids or wearables with network connectivity. The 12 finalists, selected by a renowned jury of experts, will be invited to present themselves during MEDICA 2023 on the program stage of the MEDICA CONNECTED HEALTHCARE FORUM (in Hall 12). Last year’s winner was ViewMind Inc., a company specializing in the management of neurodegenerative diseases like multiple sclerosis and Alzheimer’s. Mark Edwards, CEO and co-founder of ViewMind Inc., said that while the effects of winning cannot be quantified, “I can say that winning was very helpful to make the company and its products known”. This start-up also completed another round of financing, which was facilitated by their success at MEDICA. Already CE-marked and on the market, the ViewMind product has been validated in about 30 clinical trials on four continents. FDA approval is in progress.

ViewMind is primarily aimed at the pharmaceutical industry but also the healthcare sector in general, said Mark Edwards: “We are working on clinical trials with several pharmaceutical companies in order to give them a tool with which to find suitable participants, set up cohorts precisely and measure the effects of therapy with corresponding sensitivity.” The start-up sees itself as a pioneer for the development of precision drugs.

Edwards has been to MEDICA in Düsseldorf many times. From his point of view, the size of the event is an advantage. He has already met with many contacts from the sales sector here in order to assess possible sales partnerships. ViewMind is keeping its sights firmly on its goal as Mark Edwards explained: “We want to establish a sensitive marker for neurocognitive diseases and cognition which is as easy to operate and as useful as a device for measuring blood pressure or blood sugar.”

Business Affairs Homepage